1. Neuronal Signaling
  2. Monoamine Oxidase
  3. Rasagiline mesylate

Rasagiline mesylate (Synonyms: AGN1135 mesylate; TVP1012 mesylate)

Cat. No.: HY-14605 Purity: 99.62%
Handling Instructions

Rasagiline mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease.

For research use only. We do not sell to patients.

Rasagiline mesylate Chemical Structure

Rasagiline mesylate Chemical Structure

CAS No. : 161735-79-1

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in Water USD 66 In-stock
Estimated Time of Arrival: December 31
50 mg USD 60 In-stock
Estimated Time of Arrival: December 31
100 mg USD 90 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Rasagiline mesylate:

Top Publications Citing Use of Products

    Rasagiline mesylate purchased from MCE. Usage Cited in: Oncotarget. 2018 Jan 30;9(15):12137-12153.

    Retinal protection of Rasagiline combined with Idebenone against retinal ischemia-reperfusion (RIR) injury. Western blot analysis for the expression level of brain-derived neurotrophic factor (BDNF) in the whole IR-injured retinas.

    View All Monoamine Oxidase Isoform Specific Products:

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review


    Rasagiline mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease. Target: Monoamine Oxidase (MAO)-B Rasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug. Rasagiline is effective as monotherapy or adjunct to L-Dopa for patients with early and late Parkinson's disease (PD) [1]. Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. In several large, randomized, placebo-controlled trials, rasagiline has demonstrated efficacy as monotherapy in early PD and as adjunctive therapy in advanced PD. In addition, rasagiline has been shown to have neuroprotective effects in in vitro and in vivo studies. The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established [2]. Rasagiline has been found to be well tolerated and effective in the treatment of early PD and as adjunctive treatment in motor fluctuations. Whether rasagiline is associated with clinically significant neuroprotection (ie, disease modification) in PD is the subject of ongoing clinical trials [3].

    Clinical Trial
    Molecular Weight




    CAS No.



    CS(=O)(O)=O.C#CCN[[email protected]]1C2=CC=CC=C2CC1


    Room temperature in continental US; may vary elsewhere.

    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    H2O : 25 mg/mL (93.51 mM; Need ultrasonic)

    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.7406 mL 18.7028 mL 37.4056 mL
    5 mM 0.7481 mL 3.7406 mL 7.4811 mL
    10 mM 0.3741 mL 1.8703 mL 3.7406 mL
    *Please refer to the solubility information to select the appropriate solvent.

    Purity: 99.62%

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2


    RasagilineAGN1135TVP1012AGN 1135AGN-1135TVP 1012TVP-1012Monoamine OxidaseAutophagyApoptosisMAOInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name



    Applicant name *


    Email address *

    Phone number *


    Organization name *

    Country or Region *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product name:
    Rasagiline mesylate
    Cat. No.:
    MCE Japan Authorized Agent: